Chat with us, powered by LiveChat


Autologous Cell Therapy Market Report


Autologous Cell Therapy Market, by Therapy (Autologous Stem Cell Therapy, Autologous Cellular, Immunotherapy), Application (Oncology, Musculoskeletal disorders, Dermatology), End-User (Hospitals, Research Centers, Others): Global Opportunity Analysis and Industry Forecast, 2020–2027


Pages: 130

May 2020

The global autologous cell therapy market will witness significant growth due to the increasing demand for successful cardiac and degenerative medications. Inaddition, the drawbacks of traditional organ transplants are anticipated to fuel the demand for stem cell therapy.

Autologous Cell Therapy Market, Analysis:

Autologous cell therapy (ACT) is an innovative therapy using an individual's cells which are matured and developed outside the body and reintegrated into the recipient.The key factors contributing to the rising demand forautologous cell therapy are the growing prevalence of chronic diseases such as inflammatory disorders, cancer, a blood disorder, and others.Growing geriatric patient population, increasing cell therapy transplantations, and increasing awareness of chronic diseases are estimated to facilitate the market growth.

Increasing demand for bone marrow transplant is expected to drive the global autologous cell therapy market:

Bone marrow transplant is a procedure for replacing defective and dead cells in the bone marrow with fresh stem cells.Bone marrow is widely used for autologous cell therapy as it can support patients with a variety of cancer and non-cancer diseases. Increasing demand for bone marrow transplants is anticipated to drive the market during the forecastperiod.

Moral issues concerning embryos killing are anticipated to restrain the growth of global autologous cell therapy market:

Moral problems of killing embryos when extracting cells are a huge challenge for the global market for global autologous cell treatment;this restricts groundbreaking research on embryonic stem cells that hinders the development of the global demand for autologous cell therapy.In addition, the shortage of cell-treatment reimbursement plans may lower the market's growth.High treatment cost is another factor that further inhibits the development of this sector.

The increasing number of cancer patients worldwide is anticipated to create enormous opportunities for the global autologous cell therapy market:

According to the American Cancer Society, in the U.S., only a million people are affected bycancer, and it would only rise next year.Excess weight and bad food practices have exacerbated the global rate of disease.The continents such asAsia, Africa, and Central America alone have 60% of their cancer-stricken population;this is expected to give the global autologous cell therapy market many growth opportunities.

Autologous Cell Therapy Market, by Therapy:

Autologous stem cell therapy segment will be most lucrative till 2027

Bytherapy, the global autologous cell therapy market is divided into autologous stem cell therapy, autologous cellular, and immunotherapy.Out of these,autologous stem cell therapy is anticipated to dominate the market shares as it is used widely in many treatments such as sarcoma, lymphoma, brain tumors, and neuroblastoma. 

Autologous Cell Therapy Market, by Applications:

Oncology is estimated to dominate the global autologous cell therapy market

By application, the global autologous cell therapy market is classified into oncology, musculoskeletal disorders, and dermatology. Amongst these, oncology is anticipated to lead the market shares due to the increased number of clinical studies related to the development of cell therapies and increased adoption of regenerative medicines.

Autologous Cell Therapy Market, by End-Users:

Hospitals are estimated to be the highest growing till 2027

By end-users, the globalautologous cell therapy market is bifurcated into hospitals, research centers, and others. Amongst these, hospitals are expected to be the highest growing segment in the forecasted period asthe manufacturing firms are collaborating with clients and other partners to boost the drug progress and industrial performance of the autologous cell therapies.

Autologous Cell Therapy Market, by Region:

Asia-Pacific region will have lucrative opportunities for the market investors

The global autologous cell therapymarket is analyzed across North-America, Europe, Asia-Pacific, and LAMEA regions.North America dominates the market share mainly due to broad legislative and financial support from federal bodies for the development of this field in both the U.S. and Canada pushes the market's growth in these regions.Asia-Pacific region is anticipated to witness significant growth over the forecasted period due to increasing awareness among healthcare institutions and development in the management of chronic diseases.

To explore more about the global autologous cell therapy market, get in touch with our analysts here.

Key participants in the Global Autologous Cell Therapy Market:

Merger & acquisition andadvanced product development are the frequent strategies followed by the market players

Key participants in theGlobal Autologous Cell Therapy Market

Some of the key market players of the global autologous cell therapymarket are Fibrocell Science Inc., JCR Pharmaceuticals Co. Ltd., KolonTissueGene Inc., PHARMICELL Co. Ltd., Osiris Therapeutics Inc., MEDIPOST Co. Ltd., NuVasive, Inc., Stemedica Cell Technologies Inc., Vericel Corp., Anterogen Co Ltd., and others.

Market players prefer inorganic growth strategies to expand into local markets. The global autologous cell therapymarketplayers are emphasizing more on merger & acquisition and advanced product development.These are the strategies followed by established organizations.To emphasize more on the competitor analysis of market players, Porter's five forces model is explained in the report.



  Historical Market Estimations


  Base Year for Market Estimation


  Forecast timeline for Market Projection


  Geographical Scope

  North America, Europe, Asia-Pacific, LAMEA

  Segmentationby Therapy

  • Autologous Stem Cell Therapy
  • Autologous Cellular
  • Immunotherapy

  Segmentation by Applications

  • Oncology
  • Musculoskeletal disorders
  • Dermatology

  Segmentation by End-Users

  • Hospitals
  • Research Centers
  • Others

  Key Countries Covered

U.S., Canada, Germany, France, Spain,

Russia, Japan, China, India, South Korea, Australia, Brazil, and Saudi Arabia

  Key Companies Profiled

  • Fibrocell Science Inc.
  • JCR Pharmaceuticals Co. Ltd.
  • KolonTissueGene, Inc.
  • Osiris Therapeutics Inc.
  • MEDIPOST Co. Ltd.
  • NuVasiveInc.
  • Stemedica Cell Technologies Inc.
  • Vericel Corp.
  • Anterogen Co Ltd.

Source: Research Dive Analysis

Frequently Asked Questions

A. Fibrocell Science Inc., JCR Pharmaceuticals Co. Ltd., and KolonTissueGene Inc. are some of the key players in theglobal autologous cell therapy market.

A. The Asia-Pacificregion possesseshigh investment opportunities for investors to witness the most promising growth in the future.

A. Technological advancements,product development, along with joint ventures, are the key strategies opted by the operating companies in this market.

A. PHARMICELL Co. Ltd., Osiris Therapeutics Inc., and MEDIPOST Co. Ltd.are thecompanies investing more in R&D activities for developing new products and technologies.

Research Methodology

Purchase Options

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed